Imatinib Mesylate Tablet, Film Coated
Product Images NDC 60505-2901

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 60505-2901). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical-structure (Imatinib Molecule)

Chemical structure of Imatinib Mesylate, showing the molecular arrangement of atoms and bonds including the mesylate group.*

FDA Label Image

Imatinib100mg90s.jpg (Imatinib100mg90s)

Imatinib Mesylate 100 mg film-coated tablets packaging label for a 90-tablet bottle. The label shows storage instructions, dosage statement, and manufacturer details for Apotex Corp. The National Drug Code (NDC) is 60505-2900-9. The label is primarily white with a blue and yellow highlight on the product name and strength.*

FDA Label Image

Imatinib400mg30s.jpg (Imatinib400mg30s)

Label for Imatinib Mesylate Tablets 400 mg film-coated tablets, containing 30 tablets per package. Manufactured by Apotex Inc., Toronto, Ontario, and Apotex Corp., Weston, Florida. The label includes storage instructions, dosage strength, NDC 60505-2901-3, and the Apotex Corp logo.*

FDA Label Image

Figure-1 (Figure 1)

A Kaplan-Meier survival curve showing percentage without progression over 72 months since randomization. Two groups are compared: Imatinib Mesylate Arm (solid line) and IFN+ARA-C Arm (dashed line). The graph includes hazard ratio, log-rank test p-value, and patient numbers at various stages (progression, discontinuation, last follow-up) for both groups.*

FDA Label Image

Figure-2 (Figure 2)

A line graph comparing the percentage of patients without progression to AP (accelerated phase) or BC (blast crisis) over 72 months since randomization. Two groups are represented: Imatinib Mesylate Arm (solid line) and IFN + Ara-C Arm (dashed line). The graph includes patient numbers for progression, discontinuation, and last follow-up, hazard ratio with confidence interval, and statistical significance (P<0.001). The y-axis shows percentage without progression from 0 to 100%, and the x-axis shows months from 0 to 72.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.